Last post I ever make about $TMDX
Below are the full numbers. TMDX is expected to grow liver revenue 96% (vs. mkt at 79%), heart 72% (vs. mkt at 30%) and Lung 58% (vs. mkt at 39%).
They have now 85% mkt share in DCD liver. They are quite literally the DCD liver market
$TMDX can easily make 4x in the next 5 years!
→ It's revolutionizing organ transplants.
→ Revenue grew at 60% CAGR in the last 5 years.
→ It has a giant moat made of more than 300 patents.
Here is why I believe $TMDX is a great opportunity now👇
https://t.co/ivUEMtWgS4
1/ $TMDX is disrupting organ transplants.
It's becoming the new industry standard, yet many people don't even know what it does.
Here is everything you need to know about $TMDX, business, finances, valuation, everything.
(Thread 🧵)
For the first time in 2+ years, $CELH or $SMCI are no longer my largest positions.
In fact, as of Friday's close, $TMDX and $FOUR are now the two largest positions in my investment portfolio.
Most of you probably know I've been buying $CELH since May 2020 when the stock was in the $3s and I barely sold any shares the past 42+ months. I was actually adding to my position at the December lows when $CELH dipped below $50. Now that $CELH is up ~100% over the past few months (and up ~600% from the May 2022 lows)... I've had to trim my position over the past few weeks.
FWIW, I did transfer 1/3 of my $CELH into a separate account at the end of 2023 so I'm not including those shares when I say that $TMDX and $FOUR are now my two largest positions. I have no plans to sell those shares in CY2024 (partly for tax reasons).
$SMCI is up nearly 400% over the past 6 months when I was loading up, with the recent parabolic move I've also trimmed at position quite aggressively in the past few weeks.
As of this moment, my two highest conviction stocks for the next 12-18 months are $TMDX and $FOUR.
Both companies reported strong 2023 Q4 numbers and gave very bullish guidance for CY2024.
Last year when $TMDX gave guidance they said CY2023 revenues would be $138-145M and instead $TMDX ended up doing $241M in revenues -- they beat their original guidance by 70% and 95% of that beat was organic (they got a small bump at year end from their Summit aviation acquisition).
Investors continue to doubt this company despite $TMDX continually executing at a very high level (plus they don't have much competition right now).
$TMDX said CY2024 revenues would be $360-370M but I'm very confident they are being ultra conservative (that's just the way management operates). Their current guidance implies 49-53% YoY growth but I think $TMDX surpasses $415M+ this year which is 72% YoY growth, with an outside shot at $450M depending on a few variables which I don't want to mention yet.
In addition to strong revenue growth, $TMDX is expanding margins rapidly and should be profitable (non-GAAP) this year. Last year $TMDX lost a considerable number of transplants/procedures due to lack of access to transportation but now they won't have that problem because they've been building their own fleet of planes, currently at 11, on the way to 20.
Based on my investment model (using my own estimates), I believe $TMDX has 200% upside over the next 3-5 years so I've been using the recent pullback to add to my position.
Okay, onto $FOUR -- I've owned this stock for the better part of 2 years and they've continued to execute very well however the stock remains undervalued compared to other fintechs despite better fundamentals that most of them.
$FOUR 's valuation was absolutely ridiculous a few months ago (near the October lows) which is when the CEO mentioned they were exploring strategic alternatives which means they are willing to take the company private and/or willing to listen to acquisition offers. Over the past few months the stock has done very well (up ~80%) and then pumped even higher a couple weeks ago when rumors started circulating that $FOUR was about to be acquired by Fiserv or Amadeus.
Over the past couple weeks no deal was announced so the stock started pulling back. This weekend, the CEO of $FOUR sent an email to employees saying that several acquisition offers came in (and were reviewed) but the Board rejected all of them. I would love to know what those offers looked like but I've said multiple times over the past few weeks that I'd be very disappointed if Jared and the Board sold $FOUR for less than $120+ per share because that's what I believe this company is worth in the near future (not including any premium to getting acquired).
When $FOUR reported earnings a couple weeks ago they said CY2024 revenues would be $1.30-1.35B with $635-675M of EBITDA. If they come in at the high end of that EBITDA range it implies 47% YoY growth and I believe they can continue growing revenues by 25-30% for the next 4-5 years with similar EBITDA growth.
Wit that said, it's more than reasonable to suggest $FOUR deserves to trade at 18x EBITDA (minus the debt) which gets me to a fair market valuation in the next 12 months of $126 (using 86.19M shares which was the share count at the end of CY2023).
I still have meaningful positions in $CELH and $SMCI but I believe $TMDX and $FOUR now have more upside (from current prices/valuations) over the next 12-18 months.
I've obviously done very well with $CELH and $SMCI (plus $NVDA, $UBER, and many others) but all those gains are in the past -- as an investor I need to be looking forward and position my portfolio in a way that gives me the best odds to maximize the upside while minimizing the downside. Of course $TMDX and $FOUR could pullback over the next few weeks or even the next few months but I'm willing to average down as long as my investment thesis remains in tact, the fundamentals remain strong and the valuation remains compelling.
I expect to keep putting up big returns and I believe $TMDX are $FOUR are going to lead the way for me.
Feel free to fire off some questions, no promises that I'll answer any of them :)